CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. High bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. High threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increased Drug Development Activities
3.4.1.2. Patient Compliance offered by pharmaceutical suspensions
3.4.1.3. Availability of generic pharmaceutical suspensions
3.4.2. Restraints
3.4.2.1. Limited drug compatibility
3.4.3. Opportunities
3.4.3.1. Growing initiatives for market expansion
CHAPTER 4: PHARMACEUTICAL SUSPENSION MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Oral
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Parenteral
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: PHARMACEUTICAL SUSPENSION MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Infectious Diseases
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Cancer
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Gastrointestinal
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Neurological
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Others
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
CHAPTER 6: PHARMACEUTICAL SUSPENSION MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals and Clinics
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Home Care Settings
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Others
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: PHARMACEUTICAL SUSPENSION MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital Pharmacies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Drug Store and Retail Pharmacies
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Online Providers
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: PHARMACEUTICAL SUSPENSION MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Type
8.2.3. Market size and forecast, by Indication
8.2.4. Market size and forecast, by End User
8.2.5. Market size and forecast, by Distribution Channel
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Type
8.2.6.1.2. Market size and forecast, by Indication
8.2.6.1.3. Market size and forecast, by End User
8.2.6.1.4. Market size and forecast, by Distribution Channel
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Type
8.2.6.2.2. Market size and forecast, by Indication
8.2.6.2.3. Market size and forecast, by End User
8.2.6.2.4. Market size and forecast, by Distribution Channel
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Type
8.2.6.3.2. Market size and forecast, by Indication
8.2.6.3.3. Market size and forecast, by End User
8.2.6.3.4. Market size and forecast, by Distribution Channel
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Type
8.3.3. Market size and forecast, by Indication
8.3.4. Market size and forecast, by End User
8.3.5. Market size and forecast, by Distribution Channel
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Type
8.3.6.1.2. Market size and forecast, by Indication
8.3.6.1.3. Market size and forecast, by End User
8.3.6.1.4. Market size and forecast, by Distribution Channel
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Type
8.3.6.2.2. Market size and forecast, by Indication
8.3.6.2.3. Market size and forecast, by End User
8.3.6.2.4. Market size and forecast, by Distribution Channel
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Type
8.3.6.3.2. Market size and forecast, by Indication
8.3.6.3.3. Market size and forecast, by End User
8.3.6.3.4. Market size and forecast, by Distribution Channel
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Type
8.3.6.4.2. Market size and forecast, by Indication
8.3.6.4.3. Market size and forecast, by End User
8.3.6.4.4. Market size and forecast, by Distribution Channel
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Type
8.3.6.5.2. Market size and forecast, by Indication
8.3.6.5.3. Market size and forecast, by End User
8.3.6.5.4. Market size and forecast, by Distribution Channel
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Type
8.3.6.6.2. Market size and forecast, by Indication
8.3.6.6.3. Market size and forecast, by End User
8.3.6.6.4. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Type
8.4.3. Market size and forecast, by Indication
8.4.4. Market size and forecast, by End User
8.4.5. Market size and forecast, by Distribution Channel
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Type
8.4.6.1.2. Market size and forecast, by Indication
8.4.6.1.3. Market size and forecast, by End User
8.4.6.1.4. Market size and forecast, by Distribution Channel
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Type
8.4.6.2.2. Market size and forecast, by Indication
8.4.6.2.3. Market size and forecast, by End User
8.4.6.2.4. Market size and forecast, by Distribution Channel
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Type
8.4.6.3.2. Market size and forecast, by Indication
8.4.6.3.3. Market size and forecast, by End User
8.4.6.3.4. Market size and forecast, by Distribution Channel
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Type
8.4.6.4.2. Market size and forecast, by Indication
8.4.6.4.3. Market size and forecast, by End User
8.4.6.4.4. Market size and forecast, by Distribution Channel
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Type
8.4.6.5.2. Market size and forecast, by Indication
8.4.6.5.3. Market size and forecast, by End User
8.4.6.5.4. Market size and forecast, by Distribution Channel
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Type
8.4.6.6.2. Market size and forecast, by Indication
8.4.6.6.3. Market size and forecast, by End User
8.4.6.6.4. Market size and forecast, by Distribution Channel
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Type
8.5.3. Market size and forecast, by Indication
8.5.4. Market size and forecast, by End User
8.5.5. Market size and forecast, by Distribution Channel
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Type
8.5.6.1.2. Market size and forecast, by Indication
8.5.6.1.3. Market size and forecast, by End User
8.5.6.1.4. Market size and forecast, by Distribution Channel
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Type
8.5.6.2.2. Market size and forecast, by Indication
8.5.6.2.3. Market size and forecast, by End User
8.5.6.2.4. Market size and forecast, by Distribution Channel
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Type
8.5.6.3.2. Market size and forecast, by Indication
8.5.6.3.3. Market size and forecast, by End User
8.5.6.3.4. Market size and forecast, by Distribution Channel
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Type
8.5.6.4.2. Market size and forecast, by Indication
8.5.6.4.3. Market size and forecast, by End User
8.5.6.4.4. Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Pfizer Inc.
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. Merck & Co., Inc.
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. AstraZeneca plc
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. Eli Lilly and Company.
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Bayer AG
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.6. Sanofi
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Lupin
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.7.7. Key strategic moves and developments
10.8. Glenmark Pharmaceuticals Limited
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Novartis AG
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Teva Pharmaceutical Industries Limited
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments
| ※参考情報 薬物懸濁液は、液体中に固体粒子が分散されている状態のことを指します。そのため、薬物が水やその他の溶媒に溶けない場合でも、効率的に投与することが可能です。このような懸濁液は、特に口服剤や注射剤として広く用いられています。薬物が均一に分散しているため、効果的に吸収される利点があります。 薬物懸濁液にはいくつかの種類があります。一般的に、粒子の大きさや分散の均一性によって分類されます。小粒子の懸濁液は、体内での吸収が早いため、速効性が求められる場合に使用されます。一方、大粒子の懸濁液は、徐放性を持ち、薬物の効果を長時間持続させることができます。また、懸濁液は水性と非水性に分かれ、水性は通常、医薬品として最も一般的に使用される形態です。 薬物懸濁液の用途は多岐にわたります。特に、内服薬や医療機器に使用されることが多いですが、筋肉注射や静脈注射としても利用されます。内服薬としては、子供向けや高齢者向けに、味や飲みやすさを考慮した製品が多く見られます。また、静脈注射用としては、急速に効果を発揮するために特別に調整された懸濁液が使用されます。 薬物懸濁液を製造する際には、いくつかの重要な技術が関与しています。まず、薬物の選択とその物理化学的特性が重要です。溶解度や安定性、粒子サイズなどが考慮されます。次に、懸濁液の調製過程では、均一性を確保するために適切な界面活性剤や増粘剤が使用されます。また、製造後の均一性を維持するためには、適切な攪拌や保存条件も重要です。 さらに、薬物懸濁液は、製剤において安定性が課題となることがあります。粒子の沈降や凝集を防ぐための適切な処方が求められます。安定性を高めるためには、特に添加物の選択が肝要です。これにより、長期間にわたって品質を維持することができます。 最近では、ナノ粒子技術などの先進的なアプローチも注目されています。ナノ粒子を使用することで、薬物の生体利用率を向上させたり、標的となる細胞への配送の精度を上げたりすることが可能です。このような技術は、特に癌治療や慢性疾患の治療において、大きな可能性を秘めています。 また、懸濁液の製品化においては、ユーザーの使用感を考慮した設計が重要です。飲みやすさや保存の容易さは、患者の遵守を高める要因となります。従って、医薬品メーカーは、患者のニーズに応じた製品の開発が求められています。 このように、薬物懸濁液は多様な種類と用途を持ち、製剤技術も進化を遂げています。医薬品業界のニーズに応じて、今後も新しい製法や添加物が研究され、さらなる向上が期待される分野です。特に患者のQOL（生活の質）を向上させるための研究が進んでいることは、薬物懸濁液の重要性を一層高めています。今後の展開にも注目が集まります。 |
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
